CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
The COVID-19 pandemic has unveiled the huge challenges and risks health workers are facing globally ...
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Just a reminder that the revised client forms implement today! Don't forget to toss your o...